The FINANCIAL — Takeda Pharmaceutical Company Limited (TSE:4502) on February 17 announced the primary endpoint of progression-free survival (PFS) was not met in the Phase 3 MONET-A study of patients with stage IV non-squamous non-small cell lung cancer (NSCLC) who were randomized to treatment with investigational motesanib in combination with paclitaxel and carboplatin compared to placebo in combination with paclitaxel and carboplatin.
As a result, Takeda has elected to terminate the MONET-A trial, and will report on the full trial results once available. Motesanib is an investigational, orally administered small molecule antagonist of vascular endothelial growth factor receptors 1, 2 and 3, platelet driven growth factor receptors and stem cell factor receptor, according to Takeda.
Takeda is working with trial investigators to ensure patients who participated in the study will receive appropriate therapies.
Discussion about this post